## WWW.CCOHTA.CA

## Common Drug Review \*

Submission Review Status

Product:	Reyataz
Generic Name:	Atazanavir
Manufacturer:	Bristol-Myers Squibb

Canadian Coordinating Office for Health Technology Assessment (CCOHTA)

Submission Type: NEW Priority Review:

Date NOC Issued: 2003-Dec-05 Date Submission Received: 2003-Dec-16

Date Submission Deemed Complete (Category 1): 2004-Jan-05

Date Submission Deemed Complete (Category 1): 2004-0an-05							
Task		Time frame (Business Days)	Target Date**	Actual CDR Date	Total Time (Business Days)	Comments	
1	Check Submission Completeness	5	2003-Dec-23	2003-Dec-17	1	Missing information requested Dec 22/03. Priority review declined Dec 23/03. Missing information supplied Dec 24/03.	
2	Assign Submission Coordinator, Contract Reviewers	10	2004-Jan-19	2004-Jan-13	6		
3	Search and Retrieve Literature	10	2004-Feb-02	2004-Feb-06	18		
4	Undertake Review and Prepare Report	20	2004-Mar-01	2004-Mar-12	25		
5	Conduct Quality Assessment of Reviewers' Reports	5	2004-Mar-08	2004-Mar-17	3		
6	Comment on Reviewers' Reports (Manufacturer's Task)	7	2004-Mar-17	2004-Mar-26	7		
7	Reply to Manufacturer's Comments (Reviewer's Task)	7	2004-Mar-26	2004-Apr-06	7		
8	Prepare CEDAC Brief	5	2004-Apr-02	2004-Apr-12	3		
9	Start review by CEDAC Members	10	2004-Apr-19	2004-Apr-14	10		
10	CEDAC Meeting		2004-Apr-28	2004-Apr-28	1		
11	Send CEDAC Recommendation and Reasons for Recommendation	5	2004-May-05	2004-May-05	5		
12	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2004-May-19	2004-May-19	10	Request for Clarification received.	
13(a)	Final Recommendation sent to Drug Plans, CDRC, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5		2004-May-27		Notice of Final Recommendation issued.	
	OR						
13(b)	Clarification and Final Recommendation sent to Drug Plans, CDRC, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5					
OR							
13(c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates					
14	Final Recommendation sent to Drug Plans, CDRC, and Manufacturer	5 Following CEDAC Meeting					

<sup>\*</sup> Refer to CDR Procedures for detailed steps at http://www.ccohta.ca \*\*Tasks 2-9 are initiated AFTER submission is deemed complete.

<sup>\*\*\*</sup> The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

May 27, 2004